Unión Europea - búlgaro - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - тоцилизумаб - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - Имуносупресори - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

pharmaceutical works polfa in pabianice joint-stock co. - sulfamethopyrazine+trimethoprine - 400 mg/80 mg tablets

Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

pharmaceutical works polfa in pabianice joint-stock co. - sulfamethopyrazine+trimethoprine - 100 mg/20 mg tablets

Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

pharmaceutical works polfa in pabianice joint-stock co. - fludrocortisone - 0,1 mg tablets

Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

pharmaceutical works polfa in pabianice joint-stock co. - Ибупрофен - 200 mg coated tablets 

Bulgaria - búlgaro - Изпълнителна агенция по лекарствата

dr. a. & l. schmidgall,wolfganggasse45-47, a-1121 viena - Други лекарства, студени комбинация, други актуални продукти за ставна и мускулна болка - oral drops, solution/cutaneous solution/inhalation vapour, solution

Bulgaria - búlgaro - БАБХ (Българска агенция по безопасност на храните)

БИОФАРМ ИНЖЕНЕРИНГ АД - termoactive ензим, лекувани с антигени на вируса на болестта haemorrhagie, бактерии, pasteurella multocida, е. коли - таблетка - 0, 25 ml/0.5 ml; 0, 1 ml/0.5 ml; 0, 1 ml/0.5 ml - зайци

Unión Europea - búlgaro - EMA (European Medicines Agency)

ucb pharma sa - Цертолизумаб pegol - Болест на Крон - Имуносупресори - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia може да бъде дадено като монотерапии в случай на непоносимост към метотрексат или при продължително лечение с метотрексат е неподходящо. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.

Unión Europea - búlgaro - EMA (European Medicines Agency)

janssen-cilag international n.v. - телапревир - Хепатит c, хроничен - Антивирусни средства за системно приложение - incivo, в комбинация с пегинтерфероном алфа и рибавирином, е показан за лечение генотип 1 на хроничен хепатит в при възрастни пациенти с компенсированным заболяване на черния дроб (включително цироза):кой е за лечение наивен, които по-рано лечението интерфероном Алфа (пегилированным или пегилированным) като монотерапии или в комбинация с рибавирином, включително рецидив, частичен подсъдимите и неответчики.

Unión Europea - búlgaro - EMA (European Medicines Agency)

upjohn eesv - прегабалин - anxiety disorders; epilepsy - Противоэпилептические средства, - Нейропатическая painpregabalin pfizer е показан за лечение на периферна и Централна нейропатической болка при възрастни. epilepsypregabalin "pfizer" е показан като допълнителна терапия при възрастни с парциальными спазми С или без вторична генерализации. disorderpregabalin генерализирана тревожност pfizer е показан за лечение на генерализирано тревожно разстройство (ГТР) при възрастни.